HIROTSUバイオサイエンス | 線虫がん検査に関する世界最先端の線虫行動解析技術

NEWS

Cancer test that uses nematodes N-NOSE® （エヌノーズ）

N-NOSE is a cancer screening test takes advantage of the keen olfactory sensors of nematodes. The test has been available to the public in Japan in January 2020.

N-NOSE service site
Learn More

What is N-NOSE?

Merit of taking a cancer screening test

Why nematodes?

The world's first biological ”diagnostic” technology.

At Hirotsu Bio Science, we contribute to the development of revolutionary disease diagnostic technologies to lessen your concerns over health.

Message from CEO
Learn More

Company Profile

Company History

SDGs

Advisers

Press Release

HIROTSU Bioscience Corporation announces issuance of new shares to third-party investors

2025.03.31

HIROTSU Bioscience Corporation (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu) announces that it has implemented a Third-Party Allotment of New Shares.

More

HIROTSU Bioscience Supports Japan’s New Health Guidelines with Scientifically Validated Cancer Screening

Japan’s Ministry of Health, Labour and Welfare (MHLW) recently updated its Guidelines for New Business Activities in the Healthy Life Expectancy . . .

Demonstrating the Efficacy of N-NOSE in Detecting Hematological Malignancies was published in an international academic journal

The original research article demonstrating the efficacy of N-NOSE in detecting blood cancers (also known as hematological malignancies) has bee . . .

HIROTSU Bioscience CEO Talks Nasdaq Strategy at BEYOND 2020 “INNOVATION DAY”

Tokyo, Japan – [February 28, 2025] – HIROTSU Bioscience CEO Takaaki Hirotsu participated as a panelist at BEYOND 2020 NEXT FORUM "INNOVATION DAY . . .